Insulet Co. (NASDAQ:PODD) Shares Sold by Wolff Wiese Magana LLC

Wolff Wiese Magana LLC reduced its position in Insulet Co. (NASDAQ:PODD) by 14.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 297 shares of the medical instruments supplier’s stock after selling 51 shares during the quarter. Wolff Wiese Magana LLC’s holdings in Insulet were worth $78,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Assenagon Asset Management S.A. lifted its position in shares of Insulet by 8.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 104,392 shares of the medical instruments supplier’s stock worth $27,254,000 after buying an additional 8,102 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in Insulet in the fourth quarter valued at approximately $418,000. Ayrshire Capital Management LLC grew its holdings in shares of Insulet by 34.6% during the fourth quarter. Ayrshire Capital Management LLC now owns 22,988 shares of the medical instruments supplier’s stock valued at $6,001,000 after purchasing an additional 5,911 shares during the last quarter. Friedenthal Financial bought a new stake in shares of Insulet in the 4th quarter worth approximately $57,000. Finally, Cooper Financial Group boosted its position in Insulet by 14.2% during the 4th quarter. Cooper Financial Group now owns 1,021 shares of the medical instruments supplier’s stock valued at $267,000 after purchasing an additional 127 shares during the period.

Insulet Stock Performance

NASDAQ:PODD opened at $269.67 on Wednesday. The firm has a market capitalization of $18.92 billion, a PE ratio of 46.18, a PEG ratio of 4.12 and a beta of 1.22. The firm’s fifty day simple moving average is $264.57 and its 200 day simple moving average is $230.93. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on PODD shares. JPMorgan Chase & Co. boosted their price target on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Wells Fargo & Company increased their price objective on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. BTIG Research boosted their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Piper Sandler upped their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Finally, Citigroup boosted their price target on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

Insider Activity at Insulet

In related news, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.